Millions of women around the world live with an incurable and poorly treated condition, and many are turning to cannabis products for relief – despite inconsistent results and the risk of untested products.
For Melissa Sturgess, the CEO of London-based biotech firm Ananda Pharma, this situation presents an opportunity, she told MJBizDaily.
ADVERTISEMENT
Ananda Pharma is applying pharmaceutical-grade rigor to cannabinoid research to develop what could become the first regulator-approved CBD treatment for endometriosis, a painful condition where uterine-lining-like tissue grows outside the uterus.
This path reflects a broader shift in cannabis: credibility depends on proof, not promises, a point that’s becoming harder for the industry to ignore.
That’s a theme Sturgess will amplify next month at MJBizCon in Las Vegas.
Along with other
Read full article on Marijuana Business Daily
